Mankind Pharma Acquires 100% Stake in BSV for ₹13,630 crore

On July 25, 2024, Mankind Pharma Limited announced that it had signed a definitive agreement to acquire Bharat Serums and Vaccines Limited (BSV) from Advent International for about ₹13,630 crore, pending closing adjustments. Mankind Pharma will acquire a 100% stake in BSV by purchasing 73,086 equity shares.

The acquisition does not qualify as a related party transaction. Additionally, the promoter, promoter group, or group companies have no interest in BSV. Following the acquisition, BSV will become a wholly-owned subsidiary of Mankind Pharma.

This acquisition positions Mankind Pharma as a market leader in the Indian women’s health and fertility drug market and grants access to high-entry barrier products in critical care.

BSV, with over 50 years of biopharmaceutical leadership, has a strong R&D track record, developing recombinant and niche biologic products. BSV’s portfolio includes leading Women’s Health, Fertility, and Critical Care products. Mankind Pharma Limited has an in-house R&D centre with over 60 scientists and a strong product pipeline, offering significant growth potential through niche filings in various markets.

BSV’s Women’s Health portfolio covers the entire lifecycle from fertility to post-pregnancy. Its comprehensive fertility segment portfolio is poised for growth in both Indian and international markets, driven by increasing IVF adoption. BSV remains dedicated to providing high-quality, innovative healthcare solutions at reasonable prices to meet the needs of patients and healthcare providers globally.

Objective of Acquisition

The acquisition aims to broaden Mankind Pharma’s portfolio into complex areas with high entry barriers, particularly in women’s health, fertility, critical care, and the immunoglobulin segment. This strategic move is designed to establish Mankind Pharma as a leading player in the Indian women’s health and fertility market.

About Mankind Pharma

Mankind Pharma is an important player in the Indian pharmaceuticals market, covering a range of therapeutic areas such as anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, vitamins and minerals, and respiratory. The company also plans to expand its presence in chronic care areas.

On July 26, 2024, Mankind Pharma Ltd’s share price opened at ₹2,241.10, touching the high of ₹2,250.00 as of 10:09 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.